Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [ 3H]monoamines into synaptosomes from different regions of rat brain

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) is a recently popularized recreational drug, although some have advocated its psychotherapeutic potential. Since the pharmacology of MDMA is largely uncharacterized, the stereochemical profiles of MDMA and some of its homologs were derived on inhibition of synaptosomal uptake of [ 3H]monoamines and compared to those of amphetamine and the hallucinogenic phenylisopropylamine 2,5-dimethoxy-4-methylamphetamine (DOM). In contrast to the 5-fold stereoselectivity observed with amphetamine, only the S-(+) enantiomer of MDMA and 3,4-methylenedioxyamphetamine (MDA) inhibited [ 3H]dopamine uptake into striatal synaptosomes. Neither stereoisomer of the α-ethyl homolog of MDMA, N-methyl-l-(l,3-benzodioxol-5-yl)-2-butanamine (MBDB), inhibited [ 3H]dopamine uptake. The two stereoisomers of amphetamine and the MDMA-related compounds were equipotent in inhibiting [ 3H]norepinephrine uptake into hypothalamic synaptosomes. Both steroisomers of MDMA, MDA and MBDB were potent inhibitors of [ 3H]serotonin uptake into hippocampal synaptosomes, but only S-(+)-amphetamine produced an appreciable inhibition of [ 3H]serotonin uptake. Neither steroisomer of DOM inhibited synaptosomal uptake of any [ 3H]monoamine. These results suggest that MDMA and its homologs may be more closely related to amphetamine rather than to DOM in their biochemical mode of action. The pronounced effects of the methylenedioxy-substituted compounds on [ 3H]serotonin and [ 3H]norepinephrine uptake implicate these neurotransmitters in the pharmacological effects of these drugs.